|
1
|
Bianchini G, Balko JM, Mayer IA, Sanders
ME and Gianni L: Triple-negative breast cancer: Challenges and
opportunities of a heterogeneous disease. Nat Rev Clin Oncol.
13:674–690. 2016. View Article : Google Scholar
|
|
2
|
Marra A, Viale G and Curigliano G: Recent
advances in triple negative breast cancer: The immunotherapy era.
BMC Med. 17:902019. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Garrido-Castro A, Lin N and Polyak K:
Insights into molecular classifications of triple-negative breast
cancer: Improving patient selection for treatment. Cancer Discov.
9:176–198. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Boyle P: Triple-negative breast cancer:
Epidemiological considerations and recommendations. Ann Oncol. 23
(Suppl 6):vi7–v12. 2012. View Article : Google Scholar
|
|
5
|
Zhang C, Han Y, Huang H, Min L, Qu L and
Shou C: Integrated analysis of expression profiling data identifies
three genes in correlation with poor prognosis of triple-negative
breast cancer. Int J Oncol. 44:2025–2033. 2014. View Article : Google Scholar
|
|
6
|
Azim HA Jr, Michiels S, Bedard PL, Singhal
SK, Criscitiello C, Ignatiadis M, Haibe-Kains B, Piccart MJ,
Sotiriou C and Loi S: Elucidating prognosis and biology of breast
cancer arising in young women using gene expression profiling. Clin
Cancer Res. 18:1341–1351. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Abramson VG, Lehmann BD, Ballinger TJ and
Pietenpol JA: Subtyping of triple-negative breast cancer:
Implications for therapy. Cancer. 121:8–16. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Jakowlew SB: Transforming growth
factor-beta in cancer and metastasis. Cancer Metastasis Rev.
25:435–457. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Elliott RL and Blobe GC: Role of
transforming growth factor beta in human cancer. J Clin Oncol.
23:2078–2093. 2005. View Article : Google Scholar
|
|
10
|
Kaminska B, Wesolowska A and Danilkiewicz
M: TGF beta signalling and its role in tumour pathogenesis. Acta
Biochim Pol. 52:329–337. 2005. View Article : Google Scholar
|
|
11
|
Moses H and Barcellos-Hoff M: TGF-beta
biology in mammary development and breast cancer. Cold Spring Harb
Perspect Biol. 3:a0032772011. View Article : Google Scholar
|
|
12
|
Suriyamurthy S, Baker D, Ten Dijke P and
Iyengar PV: Epigenetic reprogramming of TGF-β Signaling in breast
cancer. Cancers. 11:7262019. View Article : Google Scholar
|
|
13
|
Li CJ, Chu PY, Yiang GT and Wu MY: The
molecular mechanism of epithelial-mesenchymal transition for breast
carcinogenesis. Biomolecules. 9:4762019. View Article : Google Scholar
|
|
14
|
Siegel PM and Massagué J: Cytostatic and
apoptotic actions of TGF-beta in homeostasis and cancer. Nat Rev
Cancer. 3:807–821. 2003. View
Article : Google Scholar : PubMed/NCBI
|
|
15
|
Bhola NE, Balko JM, Dugger TC, Kuba MG,
Sánchez V, Sanders M, Stanford J, Cook RS and Arteaga CL: TGF-β
inhibition enhances chemotherapy action against triple-negative
breast cancer. J Clin Invest. 123:1348–1358. 2013. View Article : Google Scholar
|
|
16
|
Lee YJ, Park JH and Oh SM: Activation of
NF-κB by TOPK upregulates Snail/Slug expression in TGF-β1 signaling
to induce epithelial-mesenchymal transition and invasion of breast
cancer cells. Biochem Biophys Res Commun. 530:122–129. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wang L, Xu C, Liu X, Yang Y, Cao L, Xiang
G, Liu F, Wang S, Liu J, Meng Q, et al: TGF-β1 stimulates
epithelial-mesenchymal transition and cancer-associated
myoepithelial cell during the progression from in situ to invasive
breast cancer. Cancer Cell Int. 19:3432019. View Article : Google Scholar
|
|
18
|
Syed V: TGF-β signaling in cancer. J Cell
Biochem. 117:1279–1287. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Yeo HL, Fan TC, Lin RJ, Yu JC, Liao GS,
Chen ES, Ho MY, Lin WD, Chen K, Chen CH, et al: Sialylation of
vasorin by ST3Gal1 facilitates TGF-β1-mediated tumor angiogenesis
and progression. Int J Cancer. 144:1996–2007. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kim S, Lee J, You D, Jeong Y, Jeon M, Yu
J, Kim SW, Nam SJ and Lee JE: Berberine suppresses cell motility
through downregulation of TGF-β1 in triple negative breast cancer
cells. Cell Physiol Biochem. 45:795–807. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Tan AR, Alexe G and Reiss M: Transforming
growth factor-beta signaling: Emerging stem cell target in
metastatic breast cancer? Breast Cancer Res Treat. 115:453–495.
2009. View Article : Google Scholar
|
|
22
|
Srinivasula SM and Ashwell JD: IAPs:
What's in a name? Mol Cell. 30:123–135. 2008. View Article : Google Scholar
|
|
23
|
Singh M, Chaudhry P, Fabi F and Asselin E:
Cisplatin-induced caspase activation mediates PTEN cleavage in
ovarian cancer cells: A potential mechanism of chemoresistance. BMC
Cancer. 13:2332013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ma J, Tian K, Du J, Wu Z, Wang L and Zhang
J: High expression of survivin independently correlates with tumor
progression and mortality in patients with skull base chordomas. J
Neurosurg. 132:140–149. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Khan Z, Khan N, Tiwari RP, Patro IK,
Prasad GB and Bisen PS: Down-regulation of survivin by oxaliplatin
diminishes radioresistance of head and neck squamous carcinoma
cells. Radiother Oncol. 96:267–273. 2010. View Article : Google Scholar
|
|
26
|
Lorenzetti MA, Mosna MJ, De Matteo EN,
García Lombardi M, Colli SL and Preciado MV: Overexpression of
survivin in pediatric Hodgkin lymphoma tumor cells:
Characterization of protein expression and splice-variants
transcription profile. Exp Mol Pathol. 108:24–31. 2019. View Article : Google Scholar
|
|
27
|
Stavropoulos A, Varras M, Vasilakaki T,
Varra VK, Varra FN, Tsavari A, Nonni A, Kavantzas N and Lazaris AC:
Expression of anti-apoptotic protein survivin in human endometrial
carcinoma: Clinical and pathological associations as a separate
factor and in combination with concomitant PTEN and p53 expression.
Oncol Lett. 20:1033–1054. 2020. View Article : Google Scholar
|
|
28
|
Hanif A, Lee S, Gupta M, Chander A,
Kannisto ED, Punnanitinont A, Fenstermaker R, Ciesielski M, Attwood
K, Qiu J, et al: Exploring the role of survivin in neuroendocrine
neoplasms. Oncotarget. 11:2246–2258. 2020. View Article : Google Scholar
|
|
29
|
Kapiris I, Nastos K, Karakatsanis A,
Theodosopoulos T, Karandrea D, Kondi Pafiti A and Contis J:
Survivin expression in hepatocellular carcinoma. Correlation with
clinicopathological characteristics and overall survival. J BUON.
24:1934–1942. 2019.PubMed/NCBI
|
|
30
|
Veiga GLD, Silva RDMD, Pereira EC, Azzalis
LA, Alves BDCA, Gehrke FS, Gascón TM and Fonseca FLA: The role of
survivin as a biomarker and potential prognostic factor for breast
cancer. Rev Assoc Med Bras (1992). 65:893–901. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Kennedy SM, O'Driscoll L, Purcell R,
Fitz-Simons N, McDermott EW, Hill AD, O'Higgins NJ, Parkinson M,
Linehan R and Clynes M: Prognostic importance of survivin in breast
cancer. Br J Cancer. 88:1077–1083. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Yamashita S, Masuda Y, Kurizaki T, Haga Y,
Murayama T, Ikei S, Kamei M, Takeno S and Kawahara K: Survivin
expression predicts early recurrence in early-stage breast cancer.
Anticancer Res. 27:2803–2808. 2007.PubMed/NCBI
|
|
33
|
Hinnis AR, Luckett JC and Walker RA:
Survivin is an independent predictor of short-term survival in poor
prognostic breast cancer patients. Br J Cancer. 96:639–645. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Chu JS, Shew JY and Huang CS:
Immunohistochemical analysis of survivin expression in primary
breast cancers. J Formos Med Assoc. 103:925–931. 2004.
|
|
35
|
Yamanaka K, Nakata M, Kaneko N, Fushiki H,
Kita A, Nakahara T, Koutoku H and Sasamata M: YM155, a selective
survivin suppressant, inhibits tumor spread and prolongs survival
in a spontaneous metastatic model of human triple negative breast
cancer. Int J Oncol. 39:569–575. 2011.
|
|
36
|
Shi CT, Ma J, Shi QF, Zhang Y and Wang HN:
High survivin and low zinc finger of the cerebellum 1 expression
indicates poor prognosis in triple-negative breast carcinoma. J
Breast Cancer. 22:248–259. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Lakhani SR EI, Schnitt SJ, Tan PH and van
de Vijver MJ: WHO classification of tumors of the breast. 4th
edtion. Lyon: IARC Press; 2012
|
|
38
|
Wang Q, Zhao ZB, Wang G, Hui Z, Wang MH,
Pan JF and Zheng H: High expression of KIF26B in breast cancer
associates with poor prognosis. PLoS One. 8:e616402013. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Tong D, Qu H, Meng X, Jiang Y, Liu D, Ye
S, Chen H, Jin Y, Fu S and Geng J: S-allylmercaptocysteine promotes
MAPK inhibitor-induced apoptosis by activating the TGF-β signaling
pathway in cancer cells. Oncol Rep. 32:1124–1132. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Mahotka C, Wenzel M, Springer E, Gabbert
HE and Gerharz CD: Survivin-deltaEx3 and survivin-2B: Two novel
splice variants of the apoptosis inhibitor survivin with different
antiapoptotic properties. Cancer Res. 59:6097–6102. 1999.PubMed/NCBI
|
|
41
|
Taubert H, Heidenreich C, Holzhausen HJ,
Schulz A, Bache M, Kappler M, Eckert AW, Würl P, Melcher I,
Hauptmann K, et al: Expression of survivin detected by
immunohistochemistry in the cytoplasm and in the nucleus is
associated with prognosis of leiomyosarcoma and synovial sarcoma
patients. BMC Cancer. 10:652010. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Hachim MY, Hachim IY, Dai M, Ali S and
Lebrun JJ: Differential expression of TGFβ isoforms in breast
cancer highlights different roles during breast cancer progression.
Tumour Biol. 40:10104283177482542018. View Article : Google Scholar
|
|
43
|
Kim S, Lee J, Jeon M, Lee JE and Nam SJ:
Zerumbone suppresses the motility and tumorigenecity of triple
negative breast cancer cells via the inhibition of TGF-β1 signaling
pathway. Oncotarget. 7:1544–1558. 2016. View Article : Google Scholar
|
|
44
|
Zeng K, He B, Yang BB, Xu T, Chen X, Xu M,
Liu X, Sun H, Pan Y and Wang S: The pro-metastasis effect of
circANKS1B in breast cancer. Mol Cancer. 17:1602018. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Dogu GG, Ozkan M, Ozturk F, Dikilitas M,
Er O and Ozturk A: Triple-negative breast cancer:
Immunohistochemical correlation with basaloid markers and
prognostic value of survivin. Med Oncol. 27:34–39. 2010. View Article : Google Scholar
|
|
46
|
Jha K, Shukla M and Pandey M: Survivin
expression and targeting in breast cancer. Surg Oncol. 21:125–131.
2012. View Article : Google Scholar
|
|
47
|
Li Y, Ma X, Wu X, Liu X and Liu L:
Prognostic significance of survivin in breast cancer:
Meta-analysis. Breast J. 20:514–524. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Dai JB, Zhu B, Lin WJ, Gao HY, Dai H,
Zheng L, Shi WH and Chen WX: Identification of prognostic
significance of BIRC5 in breast cancer using integrative
bioinformatics analysis. Biosci Rep. 40:BSR201936782020. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Song K, Shankar E, Yang J, Bane K,
Wahdan-Alaswad R and Danielpour D: Critical role of a
survivin/TGF-β/mTORC1 axis in IGF-I-mediated growth of prostate
epithelial cells. PLoS One. 8:e618962013. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Yang J, Song K, Krebs TL, Jackson MW and
Danielpour D: Rb/E2F4 and Smad2/3 link survivin to TGF-beta-induced
apoptosis and tumor progression. Oncogene. 27:5326–5338. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Perera CN, Chin HG, Duru N and Camarillo
IG: Leptin-regulated gene expression in MCF-7 breast cancer cells:
Mechanistic insights into leptin-regulated mammary tumor growth and
progression. J Endocrinol. 199:221–233. 2008. View Article : Google Scholar
|
|
52
|
Chen W, Zhong X, Wei Y, Liu Y, Yi Q, Zhang
G, He L, Chen F, Liu Y and Luo J: TGF-β regulates survivin to
affect cell cycle and the expression of EGFR and MMP9 in
glioblastoma. Mol Neurobiol. 53:1648–1653. 2016. View Article : Google Scholar
|
|
53
|
Neil JR, Tian M and Schiemann WP: X-linked
inhibitor of apoptosis protein and its E3 ligase activity promote
transforming growth factor-{beta}-mediated nuclear factor-{kappa}B
activation during breast cancer progression. J Biol Chem.
284:21209–21217. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Gangrade A, Pathak V, Augelli-Szafran CE,
Wei HX, Oliver P, Suto M and Buchsbaum DJ: Preferential inhibition
of Wnt/β-catenin signaling by novel benzimidazole compounds in
triple-negative breast cancer. Int J Mol Sci. 19:15242018.
View Article : Google Scholar
|
|
55
|
Hseu YC, Lin YC, Rajendran P, Thigarajan
V, Mathew DC, Lin KY, Way TD, Liao JW and Yang HL: Antrodia
salmonea suppresses invasion and metastasis in triple-negative
breast cancer cells by reversing EMT through the NF-κB and
Wnt/β-catenin signaling pathway. Food Chem Toxicol. 124:219–230.
2019. View Article : Google Scholar
|
|
56
|
Yang Z, Ji L, Jiang G, Liu R, Liu Z, Yang
Y, Ma Q and Zhao H: FL118, a novel camptothecin analogue,
suppressed migration and invasion of human breast cancer cells by
inhibiting epithelial-mesenchymal transition via the Wnt/β-catenin
signaling pathway. Biosci Trends. 12:40–46. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Ma F, Li W, Liu C, Li W, Yu H, Lei B, Ren
Y, Li Z, Pang D and Qian C: MiR-23a promotes TGF-β1-induced EMT and
tumor metastasis in breast cancer cells by directly targeting CDH1
and activating Wnt/β-catenin signaling. Oncotarget. 8:69538–69550.
2017. View Article : Google Scholar
|
|
58
|
Chen X, Duan N, Zhang C and Zhang W:
Survivin and tumorigenesis: Molecular mechanisms and therapeutic
strategies. J Cancer. 7:314–323. 2016. View Article : Google Scholar : PubMed/NCBI
|
